lundbeck, Shanes story.

Latest e-mail to Lundbeck.

To whom it concerns,

I have written to lundbeck Ireland and also lundbeck Canada on Aug 8th 2010 but am still awaiting reply. My name is Leonie and my son’s name was Shane Clancy. He was 22 before cipramil killed him but you know that already, just as you know the side effects of these drugs. Murder and suicide.

Let me just explain that I know what is going on at Lundbeck and I can also prove it. I have been in touch with John Virapen who worked for you in the Caribbean. His stories of bribing officials and doctors first class trips with all expenses paid to Denmark and corruption in general make for very interesting listening. You will not get away with murdering my son.

Leonie fennell

I would also be very interested to know if Shane’s death was logged as an adverse reaction!

Health Canada Endorsed Important Safety Information on CELEXA® (citalopram hydrobromide)

Lundbeck Canada Inc.
413 St. Jacques Street West
Suite FB-230
Montreal, QC H2Y 1N9

May 26, 2004

Subject: WARNING for SSRIs and other newer anti-depressants regarding the potential for behavioural and emotional changes, including risk of self-harm

Dear Health Care Professional,

Lundbeck Canada Inc., following discussions with Health Canada, would like to inform you of important safety information regarding the possibility that SSRIs (selective serotonin reuptake inhibitors) and other newer anti-depressants may be associated with behavioural and emotional changes, including risk of self-harm.

The Class warning incorporated in the product monograph of Celexa® (citalopram hydrobromide) is provided below.


There are clinical trial and post-marketing reports with SSRIs and other newer anti-depressants, in both pediatrics and adults, of severe agitation-type adverse events coupled with self-harm or harm to others. The agitation-type events include: akathisia, agitation, disinhibition, emotional lability, hostility, aggression, depersonalization.

1 thought on “Latest e-mail to Lundbeck.”

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s